IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fallaux et al.

Serial No.: 09/356,575

Filed: July 19, 1999

For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS

TO BE USED IN GENE THERAPY

Examiner: M Wilson

Group Art Unit: 1633

Attorney Docket No.: 3935US

NOTICE OF FEDERAL EXPRESS MAILING

Date of Deposit with USPS: October 26, 2000

Person making Deposit: Lynette Eliason

STATEMENT UNDER 37 C.F.R. §§ 1.821 through 1.825

Commissioner for Patents Washington, D.C. 20231

Sir:

- I, Allen C. Turner, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:
- 1. The enclosed paper copy of the substitute SEQUENCE LISTING, as well as the enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF), have been corrected to comply with the requirements of 37 C.F.R. §§ 1.821 through 1.824.
- 2. The enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF) is believed to be identical to the paper copy of the substitute SEQUENCE LISTING.

3. The SEQUENCE LISTINGs submitted herewith are believed to contain no "new matter" with regard to the referenced patent application.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041

Attorney for Applicants

TRASK, BRITT

P. O. Box 2550

Salt Lake City, Utah 84110

Telephone: (801) 532-1922

Date: October 26, 2000

N:\2578\3935\Second Sequence listing statement.wpd